{"disease":{"id":"malignant-melanoma","name":"Malignant melanoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":13},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"ipilimumab","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"dabrafenib","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafinlar","generic_name":"dabrafenib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase B-raf","drug_class":"Kinase Inhibitor","quality_score":68,"revenue":"1675","mechanism":"Tafinlar blocks the activity of a mutated protein called BRAF that is involved in cancer cell growth."},{"drug_id":"dabrafenib","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafinlar","generic_name":"dabrafenib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase B-raf","drug_class":"Kinase Inhibitor","quality_score":68,"revenue":"1675","mechanism":"Tafinlar blocks the activity of a mutated protein called BRAF that is involved in cancer cell growth."},{"drug_id":"encorafenib","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Braftovi","generic_name":"encorafenib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RAF proto-oncogene serine/threonine-protein kinase","drug_class":"","quality_score":83,"revenue":"716","mechanism":"Braftovi works by blocking the activity of a specific protein called BRAF that is involved in cancer cell growth."},{"drug_id":"encorafenib","indication_name":"Unresectable malignant melanoma with BRAF gene mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Braftovi","generic_name":"encorafenib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RAF proto-oncogene serine/threonine-protein kinase","drug_class":"","quality_score":83,"revenue":"716","mechanism":"Braftovi works by blocking the activity of a specific protein called BRAF that is involved in cancer cell growth."},{"drug_id":"cobimetinib","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cotellic","generic_name":"cobimetinib","company_name":"Roche","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"200","mechanism":"Cotellic works by blocking the activity of two proteins, BRAF and MEK, which are involved in the growth and spread of cancer cells."},{"drug_id":"vemurafenib","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zelboraf","generic_name":"vemurafenib","company_name":"Hoffmann La Roche","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase B-raf","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":"100","mechanism":"Zelboraf blocks the activity of the B-raf protein, which is involved in cell growth and division."},{"drug_id":"yervoy","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"vindesine","indication_name":"Malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eldisine","generic_name":"VINDESINE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"vindesine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"imlygic","indication_name":"Malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imlygic","company_name":"Johns Hopkins University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"mek162","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"mek162","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Mektovi works by blocking the MEK1 enzyme, which is a key player in the signaling pathway that promotes cancer cell growth."},{"drug_id":"mek162","indication_name":"Unresectable malignant melanoma with BRAF gene mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"mek162","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Mektovi works by blocking the MEK1 enzyme, which is a key player in the signaling pathway that promotes cancer cell growth."},{"drug_id":"talimogene-laherparepvec","indication_name":"Malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imlygic","generic_name":"TALIMOGENE LAHERPAREPVEC","company_name":"Amgen","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Imlygic is a genetically modified virus that selectively infects and kills cancer cells, stimulating an anti-tumor immune response."},{"drug_id":"aldesleukin","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proleukin","generic_name":"ALDESLEUKIN","company_name":"Chiron","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Lymphocyte Growth Factor [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"trametinib","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"trametinib","indication_name":"Malignant Melanoma with BRAF V600K Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"trametinib","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"indocyanine-green","indication_name":"Sentinel lymph node mapping in malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spy Agent Green Kit","generic_name":"INDOCYANINE GREEN","company_name":"Renew Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Diagnostic Dye","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxycarbamide","indication_name":"Malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamide","company_name":"University of Birmingham","drug_phase":"phase_3","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"proleukin","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Proleukin","company_name":"University of Minnesota","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"siklos","indication_name":"Malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Siklos","company_name":"Theravia","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zelboraf","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zelboraf","company_name":"Hoffmann-La Roche","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase, Ferrochelatase, mitochondrial, Dual specificity mitogen-activated protein kinase kinase 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xromi","indication_name":"Malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xromi","company_name":"Nova Laboratories Limited","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl476","indication_name":"Metastatic Malignant Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DACARBAZINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamid","indication_name":"Malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamid","company_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","drug_phase":"phase_2","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"interferon-alfa-2b","indication_name":"Malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dacarbazine","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dtic-Dome","generic_name":"dacarbazine","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"cobicistat","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tybost","generic_name":"COBICISTAT","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Tybost works by blocking the enzyme Cytochrome P450 3A, which is responsible for breaking down many other medications."},{"drug_id":"vindesin","indication_name":"Malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vindesin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"binimetinib","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"binimetinib","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Mektovi works by blocking a specific enzyme called MEK1, which is involved in sending signals that promote cancer cell growth."},{"drug_id":"binimetinib","indication_name":"Unresectable malignant melanoma with BRAF gene mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"binimetinib","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Mektovi works by blocking a specific enzyme called MEK1, which is involved in sending signals that promote cancer cell growth."},{"drug_id":"pembrolizuma","indication_name":"Metastatic malignant melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":33,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01772771","title":"Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04056247","title":"Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01307397","title":"A Study of Vemurafenib in Participants With Metastatic Melanoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3219,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03607578","title":"Test of Interventions to Prevent Skin Cancer Among Danes on Vacation in High UV Index Sunny Destinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":1548,"lead_sponsor_name":"Brian Køster","has_results":false},{"nct_id":"NCT03693378","title":"A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups","phase":"","overall_status":"COMPLETED","enrollment_count":1349,"lead_sponsor_name":"Immunovia, Inc.","has_results":false},{"nct_id":"NCT03116412","title":"A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT05126173","title":"DERM US and EU Validation Study","phase":"","overall_status":"COMPLETED","enrollment_count":1111,"lead_sponsor_name":"Skin Analytics Limited","has_results":false},{"nct_id":"NCT04095195","title":"Registry of Subjects at Risk of Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Associazione Italiana per lo Studio del Pancreas","has_results":false},{"nct_id":"NCT03819296","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05037825","title":"The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"VastBiome","has_results":false},{"nct_id":"NCT03820986","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":674,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03551626","title":"Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":552,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01704287","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":540,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT00864253","title":"A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":529,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT02612168","title":"Melanoma Image Analysis Algorithm (MIAA) Validation Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":514,"lead_sponsor_name":"Skin Analytics Limited","has_results":false},{"nct_id":"NCT03966456","title":"Real World Study of Four PD-1 Agents in China","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"The Affiliated Hospital of Qingdao University","has_results":false},{"nct_id":"NCT06075524","title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01689519","title":"A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":495,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06613230","title":"Improved Early Diagnosis in Female Pelvic Cancer With OC Detect","phase":"","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT04949113","title":"Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":423,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT02143999","title":"An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma","phase":"","overall_status":"COMPLETED","enrollment_count":403,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT00087776","title":"Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":393,"lead_sponsor_name":"American Regent, Inc.","has_results":false},{"nct_id":"NCT01990248","title":"An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)","phase":"","overall_status":"COMPLETED","enrollment_count":339,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06980740","title":"Video-Tumorboard PLUS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Hospital Muenster","has_results":false},{"nct_id":"NCT06500455","title":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":269,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT07371663","title":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"Beijing Tide Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT04253574","title":"Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma","phase":"","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"University of Basel","has_results":false},{"nct_id":"NCT07259304","title":"Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT07256184","title":"Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis","phase":"","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT05172232","title":"Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions","phase":"","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Linkoeping University","has_results":true},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04126876","title":"A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":214,"lead_sponsor_name":"A.J.M. van den Eertwegh","has_results":false},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04067960","title":"Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01693068","title":"Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"EMD Serono","has_results":true},{"nct_id":"NCT05551117","title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":192,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT01307267","title":"A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04079166","title":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":173,"lead_sponsor_name":"Scancell Ltd","has_results":false},{"nct_id":"NCT05094804","title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT06090266","title":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT02523313","title":"Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Prof. Dr. med. Dirk Schadendorf","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT06961006","title":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04382664","title":"UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Ultimovacs ASA","has_results":true},{"nct_id":"NCT03178851","title":"Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07428252","title":"Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Institute of Oncology Ljubljana","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}